Jim Hoffman: New Potential Predictive Biomarker for Lupus Nephritis
Jim Hoffman, Former Technical Advisor at Cygnus Technologies, LLC, shared Lupus Foundation of America’s post on LinkedIn about a recent article by Eline Jana Arends et al., published in Lupus Science and Medicine, adding:
”I find it incomprehensible at this point, given all the evidence that NETs exacerbate flares, that they are not being routinely prognostically tracked in the clinic and treated to minimize the severity of Lupus flares that can accelerate irreversible tissue and organ damage, particularly as the severity of the condition worsens and becomes increasingly refractory to systemic drug treatments.
New Potential Predictive Biomarker for Lupus Nephritis
Abstract: NET load as a novel biomarker of autoimmune activity and flare risk in SLE
What better way to study the NET effect, not only as a predictive prognostic indicator but as a highly valued clinical theranostic/theragnostic marker for direct and potentially improved treatment using this extracorporeal NET removal therapy, which can most likely also be applied to the treatment of many other lupus-like autoimmune diseases/syndromes.”
Lupus Foundation of America shared a post on LinkedIn:
”A new study finds people with systemic autoimmune rheumatic diseases like lupus and clinicians describe flares differently, especially in how quickly they start, how they are recognized, and whether they require changes in treatment.”
Title: NET load as a novel biomarker of autoimmune activity and flare risk in SLE
Authors: Eline Jana Arends, Rudmer J Postma, Sandra Van Der Kooij, Sylvia WA Kamerling, Maarten Limper, Alexandre E Voskuijl, Karina De Leeuw, Luuk B Hillbrands, Johan H Van Der Vlag, Marc Bijl, Ton J Rabelink, Cees Van Kooten, YK Onno Teng
Other posts featuring Jim Hoffman on Hemostasis Today.
-
Oct 16, 2026, 13:10Emanuel Sueldo: CAHT 2026 Celebrates Scientific Progress and Team Achievements
-
Oct 16, 2026, 13:05Maha Othman: Queen’s Health Sciences Advances CAT Risk Models and Pediatric ISTH-BAT Cut-Offs
-
Oct 16, 2026, 13:03Thrombosis Awareness Must Lead to Timely Action – Roche
-
Oct 16, 2026, 12:49Wolfgang Miesbach: 5-Year CBDR Data Confirms Emicizumab Safety and Efficacy in Hemophilia A
-
Oct 16, 2026, 12:40Edward Lee Carter: How Factor XI Inhibition Could Transform Anticoagulation Therapy
-
Oct 16, 2026, 12:40Marc Carrier: Looking Ahead to ISTH 2027 in Vancouver
-
Oct 16, 2026, 12:30Bob Lempke: How One Blood Donation Can Save Up to Three Lives
-
Oct 16, 2026, 12:30Why VWF Therapies Belong on the EU Critical Medicines List – EHC
-
Oct 16, 2026, 12:17Exploring Endothelial Cells, Genetic Fate Mapping, and Revascularization – ISTH